title: The forgotten player of in-stent restenosis: endothelial dysfunction.
abstract: Reduced coronary endothelium-dependent vasodilation may play a role in the pathophysiology of in-stent restenosis. Moreover, endothelial dysfunction may cause to progression of athetrosclerosis in coronary arteries in patients undergoing percutaneous coronary intervention, especially stent deployment. We believe that the agents improving endothelial dysfunction and healing-enhanced stents, namely vascular endothelial growth factor (VEGF)-eluting stents, estradiol-eluting stents and stents attracting endothelial cells, might take an important role in the prevention of stent restenosis strategies in the near future.
authors.forename: Turgay
authors.initials: T
authors.lastname: Celik
authors.forename: Atila
authors.initials: A
authors.lastname: Iyisoy
authors.forename: Hurkan
authors.initials: H
authors.lastname: Kursaklioglu
authors.forename: Murat
authors.initials: M
authors.lastname: Celik
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D054855:Drug-Eluting Stents; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000503:physiopathology; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D020123:Sirolimus / Q000627:therapeutic use; D042442:Vascular Endothelial Growth Factors / Q000627:therapeutic use
chemical_list: D042442:Vascular Endothelial Growth Factors; D004958:Estradiol; D020123:Sirolimus